Perceived barriers to healthcare, such as cost and inconvenience, discourage patients with positive faecal immunochemical test (FIT) results from undergoing follow-up colonoscopy for colorectal cancer (CRC) screening, according to a recent Singapore study.
Interim results of two phase III ORIENT trials presented at ESMO 2021 underscore the potential of a combination regimen comprising the PD-1 inhibitor sintilimab and chemotherapy (CT) as a first-line therapeutic alternative for gastrointestinal cancers, particularly advanced, recurrent, or metastatic oesophageal squamous cell carcinoma (SCC) and gastric/gastroesophageal junction (G/GEJ) adenocarcinoma.
Trastuzumab deruxtecan (T-Dxd) provides a highly clinically meaningful and statistically significant improvement in progression-free survival (PFS) vs trastuzumab emtansine (T-DM1) in second-line treatment of HER2-positive metastatic breast cancer (mBC), results of the phase III DESTINY-Breast03 trial have shown.
New drug applications approved by US FDA as of 01-15 September 2021 which
includes New Molecular Entities (NMEs) and new biologics. It does not
include Tentative Approvals. Supplemental approvals may have occurred
since the original approval date.
The CD19-directed chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel has demonstrated durable activity and a manageable safety profile in adult patients with relapsed or refractory (R/R) aggressive large B-cell lymphomas (LBCLs) after long-term follow-up of the JULIET trial.
The combination of lenvatinib and pembrolizumab improved progression-free survival (PFS) and overall survival (OS) compared with physician’s choice of treatment (TPC) among patients with advanced endometrial cancer with prior exposure to platinum-based therapy, regardless of DNA mismatch repair (MMR) status, according to results of a phase III study presented at IGCS 2021.
Treatment with apalutamide plus androgen deprivation therapy (ADT) results in consistently favourable pain scores and less interference from pain in the daily lives of patients with metastatic castration-sensitive prostate cancer compared with placebo plus ADT, results of the phase III TITAN study have shown. Moreover, there was no difference for change seen in fatigue with apalutamide vs placebo.
The use of pembrolizumab significantly improved disease-free survival (DFS) in patients with clear-cell renal cell carcinoma (RCC) who have undergone nephrectomy, with or without metastasectomy, and were at high risk for recurrence, according to the phase III KEYNOTE-564 trial.
Researchers from the Chinese University of Hong Kong (CUHK) have discovered a novel genetic biomarker associated with extended survival in head and neck squamous cell carcinoma (HNSCC), which is found in almost 20 percent of HNSCC tumours.
One cycle of clofarabine, cytarabine and mitoxantrone (CLAM) achieves an overall response rate (ORR) of >90 percent with a complete remission (CR) rate of nearly 70 percent in a phase II study of Hong Kong patients with refractory/relapsed acute myeloid leukaemia (R/R AML).